Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, Pedley RB, Kelland LR, Alley MC, Schultz R, Hollingshead MG, Schweikart KM, Tomaszewski JE, Sausville EA, Gregson SJ, Howard PW, Thurston DE. Hartley JA, et al. Among authors: hochhauser d. Cancer Res. 2004 Sep 15;64(18):6693-9. doi: 10.1158/0008-5472.CAN-03-2941. Cancer Res. 2004. PMID: 15374986
Measurement of Tumor Antioxidant Capacity and Prediction of Chemotherapy Resistance in Preclinical Models of Ovarian Cancer by Positron Emission Tomography.
Greenwood HE, McCormick PN, Gendron T, Glaser M, Pereira R, Maddocks ODK, Sander K, Zhang T, Koglin N, Lythgoe MF, Årstad E, Hochhauser D, Witney TH. Greenwood HE, et al. Among authors: hochhauser d. Clin Cancer Res. 2019 Apr 15;25(8):2471-2482. doi: 10.1158/1078-0432.CCR-18-3423. Epub 2019 Jan 16. Clin Cancer Res. 2019. PMID: 30651275 Free PMC article.
Drug delivery, biodistribution and anti-EGFR activity: theragnostic nanoparticles for simultaneous in vivo delivery of tyrosine kinase inhibitors and kinase activity biosensors.
Bofinger R, Weitsman G, Evans R, Glaser M, Sander K, Allan H, Hochhauser D, Kalber TL, Årstad E, Hailes HC, Ng T, Tabor AB. Bofinger R, et al. Among authors: hochhauser d. Nanoscale. 2021 Nov 18;13(44):18520-18535. doi: 10.1039/d1nr02770k. Nanoscale. 2021. PMID: 34730152 Free PMC article.
A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.
Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O'Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, Begent RH. Francis RJ, et al. Among authors: hochhauser d. Br J Cancer. 2002 Sep 9;87(6):600-7. doi: 10.1038/sj.bjc.6600517. Br J Cancer. 2002. PMID: 12237768 Free PMC article. Clinical Trial.
Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer.
Milagre CS, Gopinathan G, Everitt G, Thompson RG, Kulbe H, Zhong H, Hollingsworth RE, Grose R, Bowtell DD, Hochhauser D, Balkwill FR. Milagre CS, et al. Among authors: hochhauser d. Cancer Res. 2015 Apr 1;75(7):1255-64. doi: 10.1158/0008-5472.CAN-14-1801. Epub 2015 Feb 10. Cancer Res. 2015. PMID: 25670170 Free PMC article.
125 results